AZD6234 clinical trials
Also written AZD6234.
How each study uses AZD6234 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AZD6234 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AZD6234
- 12
Studies by the year they started
11 studies that test it; most in 2025 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test AZD6234.
- Feb 2027A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234Phase 1 · AstraZeneca
- May 2027A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234Phase 1 · AstraZeneca
- Jul 2027A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or ObesityPhase 1 · AstraZeneca
Studies
Open first, then newest update. How each study uses AZD6234 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 DiabetesNot yet recruitingPhase 3AstraZenecaNCT07922330Written as AZD6234How we know
- A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234Not yet recruitingPhase 1AstraZenecaNCT07911514Written as AZD6234 solution for injectionHow we know
- A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234RecruitingPhase 1AstraZenecaNCT07546760Written as AZD6234How we know
- A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234CompletedPhase 1AstraZenecaNCT07220954Written as AZD6234 Formulation 1How we know
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or ObesityActive, not recruitingPhase 1AstraZenecaNCT07013643Written as AZD6234How we know
- A Study in Participants With Obesity or Overweight With at Least One Weight-related ComorbidityCompletedPhase 2AstraZenecaNCT06595238Written as AZD6234How we know
- This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightActive, not recruitingPhase 2AstraZenecaNCT07017179Written as AZD6234How we know
- Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor AgonistCompletedPhase 2AstraZenecaNCT06851858Written as AZD6234How we know
- A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneCompletedPhase 2AstraZenecaNCT06862791Written as AZD6234How we know
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or ObeseCompletedPhase 1AstraZenecaNCT06132841Written as AZD6234How we know
- Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234CompletedPhase 1AstraZenecaNCT06845813Written as AZD6234How we know
- Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or ObeseCompletedPhase 1AstraZenecaNCT05511025Written as AZD6234How we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered2
- A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 DiabetesNov 6, 2026NCT07922330
- A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234Nov 2, 2026NCT07911514